News

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
Vinay Prasad was supposed to be the guy who kept Big Pharma in check. Now he’s gone.
Prasad came to the Food & Drug Administration in May, hoping to set high, evidence-based standards for new medicines. He didn't even last three months. The industry's power has never been clearer.
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake. Biogen, Argenx, Sanofi, and Bristol Myers ...
Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on the ...